<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062907</url>
  </required_header>
  <id_info>
    <org_study_id>CCL5001-01</org_study_id>
    <nct_id>NCT00062907</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corixa Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corixa Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the safety and immunogenicity of a therapeutic&#xD;
      vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with&#xD;
      early stage non-small cell lung cancer. The vaccine regimen will consist of two fixed doses&#xD;
      of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S).&#xD;
      The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the safety of the vaccine regimen&#xD;
      administered as two doses of pVAX/L523S and two doses of Ad/L523S.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To provide initial evidence as to whether CD8+ and CD4+ T cell responses specific for&#xD;
           L523S protein can be elicited by two doses of pVAX/L523S followed by two doses of&#xD;
           Ad/L523S&#xD;
&#xD;
        -  To provide initial evidence as to whether antibody responses specific for L523S protein&#xD;
           can be elicited by two doses of pVAX/L523S followed by two doses of Ad/L523S&#xD;
&#xD;
        -  To investigate the extent to which dose escalation of Ad/L523S affects the elicited&#xD;
           immune response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>9</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant DNA- pVAX/L523S</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant adenovirus- Ad/L523S</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Histologically and surgical confirmed diagnosis and stage of IB, IIA, or IIB non-small&#xD;
             cell lung cancer (NSCLC) according to the Revised International System for Staging&#xD;
             Lung Cancer&#xD;
&#xD;
          -  Primary surgical resection of lung cancer greater than or equal to 4 weeks and less&#xD;
             than or equal to 3 years prior to the Day 0 visit&#xD;
&#xD;
          -  No evidence of disease by standard diagnostic tests&#xD;
&#xD;
          -  Chest X-ray and physical examination showing no active disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  WBC count greater than or equal to 3,000 cells/mm3 and ANC greater than or equal to&#xD;
             1,500 cells/mm3&#xD;
&#xD;
          -  Hemoglobin value greater than or equal to 10.0 g/dL and a platelet count greater than&#xD;
             or equal to 125,000 cells/mm3&#xD;
&#xD;
          -  Adequate renal function (defined as serum creatinine &lt;1.5 times the upper limit of&#xD;
             normal for females and males)&#xD;
&#xD;
          -  Normal hepatic function (defined as serum bilirubin &lt;1.5 times the upper limit of&#xD;
             normal, AST &lt;2.5 times the upper limit of normal and alkaline phosphatase &lt;1.5 times&#xD;
             the upper limit of normal)&#xD;
&#xD;
          -  Ability to understand and willingness to sign an IRB-approved written consent prior to&#xD;
             study enrollment&#xD;
&#xD;
          -  Female patients must be greater than or equal to 60 years of age, or greater than or&#xD;
             equal to 5 years amenorrhea or surgically sterile&#xD;
&#xD;
          -  Male patients who are capable of fathering a child and whose partners are capable of&#xD;
             having a child must agree to use adequate contraception for 6 months after enrollment&#xD;
             (for men or women-surgical sterilization; for women-hormonal contraceptives, vaginal&#xD;
             ring or IUD)&#xD;
&#xD;
          -  Absolute CD4+ cell count of &gt;200 cells/mm3&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Received pre- or post-operative radiotherapy&#xD;
&#xD;
          -  Received prior biologic, immunologic, or gene therapy for cancer&#xD;
&#xD;
          -  Received an investigational drug (new chemical entity) within three months of study&#xD;
             entry&#xD;
&#xD;
          -  Received antibiotics within 2 weeks of Day 0 visit&#xD;
&#xD;
          -  Received systemic or inhaled corticosteroids or immunosuppressive therapy within 4&#xD;
             weeks of Day 0 visit (Use of topical corticosteroids and/or eye drops containing&#xD;
             glucocorticosteroids is acceptable)&#xD;
&#xD;
          -  History of active autoimmune diseases such as, but not limited to, systemic lupus&#xD;
             erythematosis, sarcoidosis, rheumatoid arthritis, glomerulonephritis, vasculitis, or&#xD;
             inflammatory bowel disease&#xD;
&#xD;
          -  History of bleeding in stools and/or diarrhea within 4 weeks of Day 0 visit&#xD;
&#xD;
          -  History of anaphylaxis or severe allergic reaction to vaccines or unknown allergens&#xD;
&#xD;
          -  Received any commercial vaccine within 2 weeks of Day 0 visit&#xD;
&#xD;
          -  Received a major organ allograft&#xD;
&#xD;
          -  Current or previous diagnosis of paraneoplastic syndrome&#xD;
&#xD;
          -  Evidence of a clinically significant active pulmonary infection, emphysema, FeV1 less&#xD;
             than or equal to 50% predicted, DLCO less than or equal to 50% predicted, pulse&#xD;
             oximetry less than or equal to 92% at the time of study entry&#xD;
&#xD;
          -  Known to be HIV positive&#xD;
&#xD;
          -  Results of virology screening indicate positive serology for HCV (hepatitis C virus)&#xD;
             and/or HBsAG (hepatitis B surface antigen). Positive serology for HBV antibodies is&#xD;
             allowed.&#xD;
&#xD;
          -  History of other malignancies at other sites, except effectively treated non-melanoma&#xD;
             skin cancers, superficial bladder cancer or carcinoma in situ of the cervix or an&#xD;
             effectively treated malignancy that has been in remission for greater than 5 years and&#xD;
             is highly likely to have been cured&#xD;
&#xD;
          -  Uncontrolled medical problems (neurological, cardiovascular, gastrointestinal,&#xD;
             genitourinary or other illness) considered as unwarranted high risk for&#xD;
             investigational new drug treatment&#xD;
&#xD;
          -  Patient is lactating&#xD;
&#xD;
          -  Staging classification of TX or NX or MX&#xD;
&#xD;
          -  Prior adjuvant chemotherapy within 8 weeks prior to the Day 0 visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Centers of Florida</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbi Rehm, RN</last_name>
      <phone>407-292-3042</phone>
      <email>brehm@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Barry S. Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Edwards</last_name>
      <phone>214-658-1944</phone>
      <email>jedwards@mcmrc.com</email>
    </contact>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Dunklin, RN</last_name>
      <phone>903-579-9800</phone>
      <email>linda.dunklin@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Arthur, RN</last_name>
      <phone>206-386-6921</phone>
      <email>jane.arthur@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Howard West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Miller, RN, OCN</last_name>
      <phone>509-228-1432</phone>
      <email>rosalee.miller@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Anthony, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2004</verification_date>
  <study_first_submitted>June 17, 2003</study_first_submitted>
  <study_first_submitted_qc>June 18, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2003</study_first_posted>
  <last_update_submitted>December 5, 2006</last_update_submitted>
  <last_update_submitted_qc>December 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

